LOBE

L-130 passes 12 months ongoing stabilityVANCOUVER, British Columbia, December 05, 2023--(BUSINESS WIRE)--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the Company’s lead clinical asset, L-130, a proprietary stabilize... Read More...

VANCOUVER, British Columbia, September 18, 2023--(BUSINESS WIRE)--Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases announced today that Mathew Lee will join the organization as Chief Financial Of... Read More...

Vancouver, British Columbia--(Newsfile Corp. - April 21, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today provides an update on its acquisition of the Vitamind Bran... Read More...

Appointment of Philip J. Young, CEO, as Board ChairmanVancouver, British Columbia--(Newsfile Corp. - October 13, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced that it... Read More...

Vancouver, British Columbia--(Newsfile Corp. - September 8, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease, today announced that it has closed a non-brokered private placement of unit... Read More...

Vancouver, British Columbia--(Newsfile Corp. - September 1, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into a term sheet contemplating convertible n... Read More...

Vancouver, British Columbia--(Newsfile Corp. - August 10, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into an exclusive agreement with iNGENū Pty Ltd... Read More...

Vancouver, British Columbia--(Newsfile Corp. - June 21, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe"), a Canadian Biopsychedelics company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and mental health disorders, today announced an exclusive agreement with ... Read More...

Vancouver, British Columbia--(Newsfile Corp. - June 14, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe"), a Canadian Biopharmaceutical Company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and mental health disorders is reporting its roadmap for the remainder ... Read More...

Vancouver, British Columbia--(Newsfile Corp. - June 9, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe") announces that further to the Company's June 6, 2022, news release, the record date for the six for one consolidation has been adjusted to June 10, 2022.The Canadian Securities Exchange has published a bulletin confirming ... Read More...

Vancouver, British Columbia--(Newsfile Corp. - February 24, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (the "Acquiror") announces, pursuant to the early warning requirements of Canadian securities legislation, that on February 22, 2022 and February 23, 2022, it sold a total of 4,500,000 common shares in the capital of Ionic Bra... Read More...

Vancouver, British Columbia--(Newsfile Corp. - February 16, 2022) - Lobe Sciences Ltd. (the "Acquiror") announces, pursuant to the early warning requirements of Canadian securities legislation, that on February 15, 2022, it sold 5,800,000 common shares in the capital of Ionic Brands Corp. (the "Issuer" and the common shares of the Issuer ... Read More...

Vancouver, British Columbia--(Newsfile Corp. - December 13, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") is pleased to announce that it has received approval from OTC Markets Group Inc. ("OTCM") for its shares to trade on the OTCQB®. Lobe Sciences' common stock will commence trading on the OTCQB under th... Read More...

Vancouver, British Columbia--(Newsfile Corp. - December 24, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company"), is pleased to announce that it has upsized its previously announced non-brokered private placement of units (the "Units") from $2,000,000 to up to $2,700,000 (the "Offering") and has completed a f... Read More...